After Blarcamesine, Anavex 3-71 Will Be Big(ger)
Understandably, the focus on Anavex Life Sciences Corp is centered on Anavex 2-73, blarcamesine; presently in three definitive clinical trials, for Rett syndrome, Parkinson's disease dementia (PDD), and Alzheimer's. The immediate future of Anavex depends on the clinical safety and efficacy of blarcamesine to treat at least one of these otherwise recalcitrant central nervous system (CNS) diseases. A large body of previous postings indicate the evidence why the drug is so very likely to exhibit favorable clinical outcomes.
But presently very little attention is being paid to Anavex's other new drug candidate, Anavex 3-71. I'm not going to re-post any of them, but feel free to do a postings search on Anavex 3-71. Simply, it has an even greater therapeutic potential than blarcamesine. It works therapeutically in doses fractional to those of blarcamesine; with phenomenal therapeutic outcomes against a wider diversity of CNS and other disease categories.
With Rett syndrome results soon to appear for blarcamesine, it will be the headline drug from Anavex; then even more so with the PDD results. Finally, sometime in 2024 will be the big Alzheimer's results.
But watch. waiting actively in the wings is Anavex 3-71, waiting to take the CNS (and perhaps COVID-19) treatment stage, when that act opens next year. Anavex 3-71 may end up being Anavex's biggest drug and revenue generator. Time (and clinical results) will tell. The preclinical data from murines (lab rodents), like those previously from blarcamesine, are extremely favorable; against a much wider body of diseases; particularly by muscarinic receptor activation.
As a retail (private individual) holder of a moderate AVXL position (several thousand shares), I've perceived from my Anavex investment start, about five or six years ago, that this investment would take a lengthy period to pay off. On paper (well, on my spreadsheet) I have a very nice value appreciation of my AVXL position. But I've never sold a share (have taken no profits), and don't intend to for many years. Knowing to a reasonable degree the biochemical intricacies of the biochemistry of the Anavex molecules, I'm satisfied to patiently wait for Anavex to gain FDA approval to sell one of their drugs. In 2023, my spreadsheet cells indicating AVXL share prices will have to add another digit or two. In the Total Value cells (share price x number of shares), at least two digits will have to be added there, too.
A worthwhile wait.
AI
Market Data 
Markets 
